Stability matters: radiochemical stability of therapeutic radiopharmaceutical 177Lu-PSMA I&T
M Vyas, R Lim, J Fagan… - Journal of Nuclear …, 2022 - Soc Nuclear Med
Labeling radiopharmaceuticals and testing the quality of the labeled product before injecting
it into patients are standard operating procedures in the nuclear medicine department. There …
it into patients are standard operating procedures in the nuclear medicine department. There …
[HTML][HTML] Quality control of [177Lu]Lu-PSMA preparations using HPLC: effect of sample composition and ligand on recovery
EA Aalbersberg, TT Cao, MM Geluk-Jonker… - EJNMMI …, 2022 - Springer
Abstract Background [177Lu] Lu-PSMA is used for the treatment of metastatic castration-
resistant prostate cancer. For in-house productions, quality control methods are essential for …
resistant prostate cancer. For in-house productions, quality control methods are essential for …
[HTML][HTML] Improved quality control of [177Lu]Lu-PSMA I&T
M Kraihammer, P Garnuszek, A Bauman… - EJNMMI …, 2023 - Springer
Background Targeted radionuclide therapy with [177Lu] Lu-PSMA I&T (zadavotide
guraxetan) has proven high efficacy and safety in treating patients with advanced prostate …
guraxetan) has proven high efficacy and safety in treating patients with advanced prostate …
[HTML][HTML] Radiolabeling and quality control of therapeutic radiopharmaceuticals: optimization, clinical implementation and comparison of radio-TLC/HPLC analysis …
EL Hooijman, CM Ntihabose, TGA Reuvers… - EJNMMI …, 2022 - Springer
Background Radiopharmaceuticals are considered as regular medicinal products and
therefore the same regulations as for non-radioactive medicinal products apply. However …
therefore the same regulations as for non-radioactive medicinal products apply. However …
[HTML][HTML] Liquid Chromatography ICP-MS to Assess the Stability of 175Lu- and natGa-Based Tumor-Targeting Agents towards the Development of 177Lu- and 68Ga …
In recent years, nuclear medicine has gained great interest, partly due to the success story of
[177Lu] Lu-PSMA-617 (PluvictoTM). Still, in-depth preclinical characterization of …
[177Lu] Lu-PSMA-617 (PluvictoTM). Still, in-depth preclinical characterization of …
Synthesis of 18F-PSMA-1007 injection using single use cassette for GMP production
S Naka, T Watabe, F Soeda, Y Kanai, O Neels… - 2018 - Soc Nuclear Med
1036 Objectives: The prostate-specific membrane antigen (PSMA) is a major target for the
theragnostics in prostate cancer. In recent years, many PET tracers targeting PSMA have …
theragnostics in prostate cancer. In recent years, many PET tracers targeting PSMA have …
[HTML][HTML] Preparation of 177Lu-PSMA-617 in Hospital Radiopharmacy: Convenient Formulation of a Clinical Dose Using a Single-Vial Freeze-Dried PSMA-617 Kit …
M Guleria, J Amirdhanayagam, HD Sarma… - BioMed Research …, 2021 - hindawi.com
Objective. In the recent time, endoradionuclide therapy for metastatic castration-resistant
prostate carcinoma employing 177 Lu-PSMA-617 has yielded encouraging results and …
prostate carcinoma employing 177 Lu-PSMA-617 has yielded encouraging results and …
[HTML][HTML] Quality Assurance Investigations and Impurity Characterization during Upscaling of [177Lu]Lu-PSMAI&T
S Schmitl, J Raitanen, S Witoszynskyj, EM Patronas… - Molecules, 2023 - mdpi.com
[177Lu] Lu-PSMAI&T is widely used for the radioligand therapy of metastatic castration-
resistant prostate cancer (mCRPC). Since this kind of therapy has gained a large momentum …
resistant prostate cancer (mCRPC). Since this kind of therapy has gained a large momentum …
[CITATION][C] Editorial (Thematic Issue: Lutetium-177 Labeled Therapeutics: 177Lu-PSMA is Set to Redefine Prostate Cancer Treatment)
A MR Pillai, FF Russ Knapp - Current Radiopharmaceuticals, 2016 - ingentaconnect.com
The developing success of 177Lu as a therapeutic radionuclide can be mainly attributed to
its use in the treatment of neuroendocrine tumors (NETs). Although 177Lu-DOTATATE is yet …
its use in the treatment of neuroendocrine tumors (NETs). Although 177Lu-DOTATATE is yet …
[HTML][HTML] Production and Quality Control of [177Lu]Lu-PSMA-I&T: Development of an Investigational Medicinal Product Dossier for Clinical Trials
V Di Iorio, S Boschi, C Cuni, M Monti, S Severi… - Molecules, 2022 - mdpi.com
Since prostate cancer is the most commonly diagnosed malignancy in men, the theranostic
approach has become very attractive since the discovery of urea-based PSMA inhibitors …
approach has become very attractive since the discovery of urea-based PSMA inhibitors …
Related searches
- radiochemical stability 177lu psma
- therapeutic radiopharmaceutical 177lu psma
- therapeutic radiopharmaceutical radiochemical stability
- psma i&t product dossier
- psma i&t quality control
- thematic issue 177lu psma
- therapeutic radiopharmaceuticals radio tlc
- therapeutic radiopharmaceuticals clinical implementation
- therapeutic radiopharmaceuticals quality control
- thematic issue prostate cancer treatment
- liquid chromatography icp ms
- stability matters 177lu psma
- therapeutic radiopharmaceutical stability matters
- labeled therapeutics 177lu psma
- therapeutic radiopharmaceuticals lu psma